68Ga-FAPI-46 PET在癌症患者中的辐射剂量学与生物分布
该研究对6例不同癌症患者行68Ga-FAPI-46 PET/CT连续扫描(注射后10分钟、1小时、3小时),用OLINDA/EXM 1.1计算器官吸收剂量与有效剂量。结果显示全身平均有效剂量为7.80E-03 mSv/MBq,给予200 MBq时估计全身剂量约5.3 mSv;肿瘤与本底比值随时间升高,提示显像性能良好且示踪动力学适合潜在治疗应用。
要点
- 膀胱壁有效剂量最高(2.41E-03 mSv/MBq),其次为卵巢和红骨髓。
- 全身平均有效剂量7.80E-03 mSv/MBq,200 MBq给药估计全身剂量约5.3 mSv。
- 除子宫外各器官肿瘤与本底比值随时间升高,肿瘤滞留时间优于FAPI-04。
核心结论
- 68Ga-FAPI-46 PET/CT具有较好的剂量学特征,生物分布显示高且随时间升高的肿瘤与本底比值,提示诊断性能良好并具备潜在治疗应用的示踪动力学。
研究设计与样本
- 研究纳入6例不同癌症患者,于注射68Ga-FAPI-46后10分钟、1小时、3小时行系列PET/CT扫描。
- 源器官包括肾、膀胱、肝、心、脾、骨髓、子宫及全身其余部分,采用OLINDA/EXM软件1.1拟合器官动力学数据。
- 由勾画的肿瘤与源器官体积生成SUV和肿瘤与本底比值,肌肉与血池球形体素用于计算比值。
主要发现
- 所有时间点平均SUVmax均以肝脏最高,肿瘤与器官SUVmean随时间下降。
- 除子宫外各器官的肿瘤与本底比值随时间升高。
- 有效剂量最高的器官为膀胱壁2.41E-03 mSv/MBq,其次为卵巢1.15E-03 mSv/MBq和红骨髓8.49E-04 mSv/MBq。
- 全身平均有效剂量为7.80E-03 mSv/MBq。
关键数值与推荐
- 给予200 MBq(5.4 mCi)68Ga-FAPI-46时估计全身剂量为5.3 mSv,其中PET示踪剂贡献1.56 ± 0.26 mSv,1次低剂量CT扫描贡献3.7 mSv。
- 器官有效剂量:膀胱壁2.41E-03 mSv/MBq、卵巢1.15E-03 mSv/MBq、红骨髓8.49E-04 mSv/MBq。
临床怎么用
- 可参考该剂量学数据评估68Ga-FAPI-46 PET/CT的辐射风险并规划给药活度。
- 利用比值随时间升高的动力学特点选择延迟显像时间点以优化病灶检出。
局限性
- 研究仅纳入6例不同癌症患者,样本量小。
- 仅设10分钟、1小时、3小时3个扫描时间点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Targeting cancer-associated fibroblasts (CAFs) has become an attractive goal for diagnostic imaging and therapy because they can constitute as much as 90% of a tumor mass. The serine protease fibroblast activation protein (FAP) is overexpressed selectively in CAFs, drawing interest in FAP as a stromal target. The quinoline-based FAP inhibitor (FAPI) PET tracer 68Ga-FAPI-04 has been previously shown to yield high tumor-to-background ratios (TBRs) in patients with various cancers. Recent developments toward an improved compound for therapeutic application have identified FAPI-46 as a promising agent because of an increased tumor retention time in comparison with FAPI-04. Here, we present a PET biodistribution and radiation dosimetry study of 68Ga-FAPI-46 in cancer patients. Methods: Six patients with different cancers underwent serial 68Ga-FAPI-46 PET/CT scans at 3 time points after radiotracer injection: 10 min, 1 h, and 3 h. The source organs consisted of the kidneys, bladder, liver, heart, spleen, bone marrow, uterus, and remainder of body. OLINDA/EXM software, version 1.1, was used to fit and integrate the kinetic organ activity data to yield total-body and organ time-integrated activity coefficients and residence times and, finally, organ-absorbed doses. SUVs and TBR were generated from the contoured tumor and source-organ volumes. Spheric volumes in muscle and blood pool were also obtained for TBR (tumor SUVmax/organ SUVmean). Results: At all time points, average SUVmax was highest in the liver. Tumor and organ SUVmean decreased over time, whereas TBRs in all organs but the uterus increased. The organs with the highest effective doses were bladder wall (2.41E-03 mSv/MBq), followed by ovaries (1.15E-03 mSv/MBq) and red marrow (8.49E-04 mSv/MBq). The average effective total-body dose was 7.80E-03 mSv/MBq. Conclusion:68Ga-FAPI-46 PET/CT has a favorable dosimetry profile, with an estimated whole-body dose of 5.3 mSv for an administration of 200 MBq (5.4 mCi) of 68Ga-FAPI-46 (1.56 ± 0.26 mSv from the PET tracer and 3.7 mSv from 1 low-dose CT scan). The biodistribution study showed high TBRs increasing over time, suggesting high diagnostic performance and favorable tracer kinetics for potential therapeutic applications.
引用
- Meyer C, Dahlbom M, Lindner T, et al. Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients. J Nucl Med. 2019. PMID: 31836685. doi:10.2967/jnumed.119.236786
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。